The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients

International Journal of Neuropsychopharmacology

Volumn 16, Issue 6, 2013, Pages 1421-1425

  Reynolds, Gavin P ^a   Yevtushenko, Olga O ^a   Gordon, Sarah ^a   Arranz, Belen ^b   San, Luis ^b   Cooper, Stephen J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic drugs; FTO gene; metabolic syndrome; obesity; weight gain

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; FEMALE; FTO GENE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; CHRONIC DISEASE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; OBESITY; POLYMORPHISM, GENETIC; PROTEINS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84878829550     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001435     Document Type: Article

References (11)

1. Arranz B, Rosel P, Raḿrez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive firstepisode schizophrenia patients. J Clin Psychiatry 65:1335-1342.
2. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87-93.
3. Fawcett KA, Barroso I (2010) The genetics of obesity : FTO leads the way. Trends Genet 26:266-274.
4. Frayling TM et al. (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889-894.
5. Perez-Iglesias R, Mata I, Amado JA, Berja A, Garcia-Unzueta MT, Mart́nez Garća O, Arranz MJ, Vazquez-Barquero JL, Crespo-Facorro B (2010) Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmacol 30:661-666.
6. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169-179.
7. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Aml J Psychiatry 160:284-289.
8. Templeman LA, Reynolds GP, Arranz B, San L (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195-200.
9. Wang P, Yang FJ, Du H, Guan YF, Xu TY, Xu XW, Su DF, Miao CY (2011) Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol Med 17:523-532.
10. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP (2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192:424-428.
11. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58-62.